← Leaderboards
Lark L Coffey
University Of California At Davis
$8,929,666
Attributed
$19,248,929
Total exposure
7
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $6.7M · FY2016–25$10M$7.5M$5M$2.5M$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$19,248,929 · 7
By mechanism
R01$9,019,830 · 3
U01$8,892,861 · 1
R21$1,336,238 · 3
Top collaborators
- Christopher M Barker8 shared
- Tierra Smiley Evans8 shared
- Christine Kreuder Johnson8 shared
- Amy Celeste Morrison8 shared
- Angela Mariah Bosco-Lauth1 shared
- Daniel N Streblow1 shared
Most similar at University Of California At Davis
Same institution · by research overlap
- Amy Celeste Morrison$4,317,239
- Tierra Smiley Evans$3,323,549
- Christopher M Barker$14,027,468
- Christine Kreuder Johnson$1,778,572
Others in their field
Top investigators on “Virus”
- David Heimbrook · Leidos Biomedical Research, Inc.$512,873,478
- Lawrence Corey · Fred Hutchinson Cancer Center$392,679,667
- Barton F Haynes · Duke University$328,711,626
- Dennis R. Burton · Scripps Research Institute$276,624,892
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$274,342,142
- Richard Webby · St. Jude Children'S Research Hospital$265,067,789
Research focus
VirusTransmission ProcessCulicidaeViralVectorFeverDisease OutbreaksPersonsInfectionCohortResourcesVirus DiseasesAreaAnimalsRna VirusesCellsResponseVector MosquitoEpidemiologyMosquito-BorneCountryViral TransmissionPredispositionDeep Sequencing
Grant awards (21)
Vaccine-mediated cross-alphavirus protection for a live attenuated FDA licensed chikungunya virus vaccine$3,248,576
R01 · FY2025 · AI · contact PI
Transmission dynamics and fitness of reemerging St. Louis encephalitis virus in mosquito vectors and West Nile virus naïve and immune avian reservoirs$3,161,373
R01 · FY2025 · AI · contact PI
Adaptation of Mayaro virus to urban mosquitoes$241,500
R21 · FY2025 · AI · contact PI
EpiCenter for Emerging Infectious Disease Intelligence$1,525,120
U01 · FY2024 · AI
EpiCenter for Emerging Infectious Disease Intelligence$391,379
U01 · FY2024 · AI
Transmission dynamics and fitness of reemerging St. Louis encephalitis virus$201,250
R21 · FY2024 · AI · contact PI
Adaptation of Mayaro virus to urban mosquitoes$201,146
R21 · FY2024 · AI · contact PI
Collaborative cross mice as a new model for diverse human outcomes of St. Louis encephalitis virus disease$199,187
R21 · FY2024 · AI · contact PI
EpiCenter for Emerging Infectious Disease Intelligence$1,555,321
U01 · FY2023 · AI
EpiCenter for Emerging Infectious Disease Intelligence$398,937
U01 · FY2023 · AI
Collaborative cross mice as a new model for diverse human outcomes of St. Louis encephalitis virus disease$253,155
R21 · FY2023 · AI · contact PI
Transmission dynamics and fitness of reemerging St. Louis encephalitis virus$240,000
R21 · FY2023 · AI · contact PI
EpiCenter for Emerging Infectious Disease Intelligence$1,581,195
U01 · FY2022 · AI
EpiCenter for Emerging Infectious Disease Intelligence$1,613,124
U01 · FY2021 · AI
SARS-CoV-2 genomic variant surveillance in human and non-human primate populations in Peru$149,998
U01 · FY2021 · AI
EpiCenter for Emerging Infectious Disease Intelligence$1,677,787
U01 · FY2020 · AI
Engineering high fidelity mutations to increase safety of live-attenuated alphavirus vaccines$538,306
R01 · FY2020 · AI · contact PI
Engineering high fidelity mutations to increase safety of live-attenuated alphavirus vaccines$539,172
R01 · FY2019 · AI · contact PI
Engineering high fidelity mutations to increase safety of live-attenuated alphavirus vaccines$541,786
R01 · FY2018 · AI · contact PI
Engineering high fidelity mutations to increase safety of live-attenuated alphavirus vaccines$541,923
R01 · FY2017 · AI · contact PI
Engineering high fidelity mutations to increase safety of live-attenuated alphavirus vaccines$448,694
R01 · FY2016 · AI · contact PI